FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration. This bicarbonate-free, phenol-red-free, HEPES-free base gives researchers full control of the buffering system for metabolic-flux, imaging, and Seahorse XF workflows.

• Quadruple-stage nano-filtration reaching 0.04 µm (0.1 µm ×2 + 0.04 µm ×2), validated across four sequential passes for microchannel-safe purity
• Endotoxin release specification < 0.05 EU/mL (LAL assay, USP <85> BET), controlled per manufacturing batch
• RPMI 1640 high-glucose base (4500 mg/L) with 300 mg/L L-glutamine and 110 mg/L sodium pyruvate for complete central-carbon metabolism support
• Formulated without sodium bicarbonate, HEPES, or phenol red — a chemically defined, bicarbonate-free base compatible with Agilent Seahorse XF real-time metabolic assays
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm) under ISO Class 5 aseptic fill and finish
• Manufactured under an ISO 13485:2016 quality management system, with final packaging and testing at Diagnocine, Totowa, New Jersey
• Custom pH, glucose, salt, HEPES, and nutrient formulations available on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and endotoxin variability that accumulate inside microchannels — corrupting biosensor readings, triggering inflammation in primary cultures, and shortening device lifetimes. FluxMPS™ is engineered to address these failure modes at the source.

Quadruple-stage filtration system

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid is processed through a four-stage serial filtration sequence — two dedicated prefilter-and-final-filter pairs — reaching a 0.04 µm final cut-off, addressing mycoplasma-sized particulates and subvisible debris that single-pass 0.22 µm filtration cannot.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris and protein aggregates; protects the first 0.04 µm final-filter cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm final-filter cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill and finish under ISO Class 5 laminar-flow conditions.

Designed for next-generation cell culture platforms

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid is suited to organ-on-a-chip, metabolic-flux, Seahorse XF, and live-cell imaging workflows where particulate contamination and buffer interference are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Lot-release quality parameters

Every production lot of FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid undergoes the complete quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from the manufacturer specification. Total: 39 components across 4 categories (Inorganic Salts, Amino Acids, Vitamins, Others). Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS, with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-RPMIG-BR1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered RPMI 1640 alternatives.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting the scientific rationale for ultra-filtered, bicarbonate-free media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Kim S et al. (2012). Gut-on-a-chip microdevice replicates key functional features of the human intestine. Lab on a Chip, 12(12), 2165–2174. doi:10.1039/c2lc40074j
6. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
7. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
8. Buttgereit F & Brand MD (1995). A hierarchy of ATP-consuming processes in mammalian cells. Biochemical Journal, 312(1), 163–167. doi:10.1042/bj3120163
9. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175
10. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539